Impact of PET/CT system, reconstruction protocol, data analysis method, and repositioning on PET/CT precision: An experimental evaluation using an oncology and brain phantom

Purpose: In longitudinal oncological and brain PET/CT studies, it is important to understand the repeatability of quantitative PET metrics in order to assess change in tracer uptake. The present studies were performed in order to assess precision as function of PET/CT system, reconstruction protocol, analysis method, scan duration (or image noise), and repositioning in the field of view. Methods: Multiple (repeated) scans have been performed using a NEMA image quality (IQ) phantom and a 3D Hoffman brain phantom filled with 18F solutions on two systems. Studies were performed with and without randomly (< 2 cm) repositioning the phantom and all scans (12 replicates for IQ phantom and 10 replicates for Hoffman brain phantom) were performed at equal count statistics. For the NEMA IQ phantom, we studied the recovery coefficients (RC) of the maximum (SUVmax), peak (SUVpeak), and mean (SUVmean) uptake in each sphere as a function of experimental conditions (noise level, reconstruction settings, and phantom repositioning). For the 3D Hoffman phantom, the mean activity concentration was determined within several volumes of interest and activity recovery and its precision was studied as function of experimental conditions. Results: The impact of phantom repositioning on RC precision was mainly seen on the Philips Ingenuity PET/CT, especially in the case of smaller spheres (< 17 mm diameter, P < 0.05). This effect was much smaller for the Siemens Biograph system. When exploring SUVmax, SUVpeak, or SUVmean of the spheres in the NEMA IQ phantom, it was observed that precision depended on phantom repositioning, reconstruction algorithm, and scan duration, with SUVmax being most and SUVpeak least sensitive to phantom repositioning. For the brain phantom, regional averaged SUVs were only minimally affected by phantom repositioning (< 2 cm). Conclusion: The precision of quantitative PET metrics depends on the combination of reconstruction protocol, data analysis methods and scan duration (scan statistics). Moreover, precision was also affected by phantom repositioning but its impact depended on the data analysis method in combination with the reconstructed voxel size (tissue fraction effect). This study suggests that for oncological PET studies the use of SUVpeak may be preferred over SUVmax because SUVpeak is less sensitive to patient repositioning/tumor sampling.

[1]  A. Lammertsma,et al.  Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-d-glucose and positron emission tomography: an overview of different analytical methods , 2000, European Journal of Nuclear Medicine.

[2]  Y. Koyama,et al.  FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses , 2003, Skeletal Radiology.

[3]  Johan Nuyts,et al.  Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  R. Boellaard Standards for PET Image Acquisition and Quantitative Data Analysis , 2009, Journal of Nuclear Medicine.

[5]  Drew A. Torigian,et al.  Repeatability of 18F-FDG PET/CT in Advanced Non–Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials , 2015, The Journal of Nuclear Medicine.

[6]  M. Schwaiger,et al.  Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  R. Boellaard,et al.  Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  Eric J. W. Visser,et al.  FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  R. Boellaard,et al.  Repeatability of 18F-FDG PET in a Multicenter Phase I Study of Patients with Advanced Gastrointestinal Malignancies , 2009, Journal of Nuclear Medicine.

[10]  Akira Maebatake,et al.  Influence of Statistical Fluctuation on Reproducibility and Accuracy of SUVmax and SUVpeak: A Phantom Study , 2015, The Journal of Nuclear Medicine Technology.

[11]  Adriaan A. Lammertsma,et al.  Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  W. Oyen,et al.  FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  J. Matthews,et al.  Impact of point spread function modelling and time of flight on FDG uptake measurements in lung lesions using alternative filtering strategies , 2014, EJNMMI Physics.

[14]  M. J. Fusselman,et al.  Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose. , 1996, Radiology.

[15]  Adriaan A. Lammertsma,et al.  Measuring [18F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  Paul Kinahan,et al.  Evaluation of strategies towards harmonization of FDG PET/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  Jason P Fine,et al.  Influence of reconstruction iterations on 18F-FDG PET/CT standardized uptake values. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  J Aoki,et al.  FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. , 2001, Radiology.

[20]  Paul Kinahan,et al.  Instrumentation factors affecting variance and bias of quantifying tracer uptake with PET/CT. , 2010, Medical physics.

[21]  Arman Rahmim,et al.  Resolution modeling in PET imaging: Theory, practice, benefits, and pitfalls. , 2013, Medical physics.

[22]  K F Hübner,et al.  Differentiating benign from malignant lung lesions using "quantitative" parameters of FDG PET images. , 1996, Clinical nuclear medicine.

[23]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[24]  Martin A Lodge,et al.  Noise Considerations for PET Quantification Using Maximum and Peak Standardized Uptake Value , 2012, The Journal of Nuclear Medicine.

[25]  Ronald Boellaard,et al.  Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non–Small Cell Lung Cancer Patients , 2016, The Journal of Nuclear Medicine.